FindTrial
Sign In

Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)

Study of seroPREvalence Vis-à-vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04528901
Acronym
PRESAGE
Enrollment
1080
Registered
2020-08-27
Start date
2020-09-04
Completion date
2022-12-31
Last updated
2021-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Brief summary

seroPREvalence vis-à-vis SARS-CoV2 and correlation with clinical forms of COVID-19 in patients followed in Pulmonology in the cluster area of the Grand-Est region.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Man or woman from 18 years old and without upper age limit * Patient followed in pulmonology at Strasbourg University Hospital * Patient presenting at least one of the following pathologies: 1. severe persistent asthma (200 patients) 2. chest cancer that is active or has received treatment within a period of less than one year (300 patients) 3. history of lung transplantation performed before the start of the epidemic (02/29/2020) (300 patients) 4. idiopathic or other diffuse interstitial lung disease, sarcoidosis or vasculitis (70 patients) 5. pulmonary arterial hypertension (PAH) (group 1 of the international classification) any cause or chronic thromboembolic PAH (group 4): (60 patients) 6. Severe COPD in the respiratory failure stage (150 patients) * Subject affiliated to a social health insurance protection scheme * Subject able to understand the objectives of the research * Subject having signed an informed consent

Exclusion criteria

* Inability to provide informed information about the subject (subject in an emergency situation, difficulty in understanding the subject, etc.) * Subject under safeguard of justice * Subject under guardianship or guardianship

Design outcomes

Primary

MeasureTime frameDescription
Determine and compare the seroprevalence for SARS-CoV2 among patients with respiratory pathologies monitored in Pneumology at the Strasbourg University Hospital, in the cluster zone of the Grand Est.15 monthsCarrying out a serological assay of specific antibodies to SARS-CoV-2

Countries

France

Contacts

Primary ContactCéline MASCAUX
Celine.mascaux@chru-strabourg.fr+ 3 33 69 55 06 44

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026